Our Biofunctional Nanomaterials group research the design and development of self-assembling nanostructures/platforms for biomedical applications based on the building blocks of life, namely peptide and their unnatural variants (peptide-mimetics).
These structures have the ability to form nanofibrous hydrogels or nanotubular structures with high surface to volume ratios in the presence of specific physiological stimuli (e.g. pH, temperature, enzymes). They have huge potential within the fields of drug delivery and biomaterials with the group’s focus primarily on the development of antimicrobial and anticancer technologies, sustained release drug delivery systems (injectable implants) and molecules with the ability to transverse the biological barriers (e.g. blood-brain barrier, outer membrane of Gram-negative bacteria).
Our most recent work relates to the development of self-assembling peptide-based hydrogel materials for use against infection and as long releasing implants for diseases with medication adherence issues (e.g. HIV/AIDs).
Harnessing a “bottom-up” approach, variation of the primary amino acid sequence of peptides allows structures to spontaneously assemble into ordered nanostructures upon exposure to varying environmental factors/stimuli. The peptide backbone provides a unique primer for tailoring biocompatibility, biodegradability and functionality.
We have interest in developing these technologies with the ultimate goal of translating them into healthcare products for patient benefit, working closely with our academic partners, funding agencies, charities, industry, clinicians and the public.
Funding for Medical Research Council: Confidence in Concept Project
25 April, 2020
We are happy to announce our group has received funding as part of the MRC CiC programme (£67,867) to study the use of antiretroviral drugs in HIV/AIDs prevention alongside our industry partners. Funding will enable a Research Fellow to work within our group on this project for one year. We should hopefully be in a […]
Group receive major funding from EPSRC to develop peptide-like hydrogels for combined HIV-contraceptive therapy
03 September, 2019
We are excited to announce support from the Engineering and Physical Sciences Research Council (EPSRC) to develop of peptide-like hydrogels for use as a long-acting injectable delivery platform for combined HIV-contraceptive drug delivery. Total support (£766,542) will allow further development of our peptide-mimetic platforms in a key healthcare area in collaboration with our co-investigators at […]